[
  {
    "ts": null,
    "headline": "Model Portfolio For Capital Appreciation, September 2025",
    "summary": "Discover 20 top stocks & 2 ETFs for capital appreciation.",
    "url": "https://finnhub.io/api/news?id=8f0c4de44ea1f1c1c90b42526ac3e93041074b49a2cd0d6bb87d81a3e8640aad",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759101203,
      "headline": "Model Portfolio For Capital Appreciation, September 2025",
      "id": 136911301,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/482730527/image_482730527.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover 20 top stocks & 2 ETFs for capital appreciation.",
      "url": "https://finnhub.io/api/news?id=8f0c4de44ea1f1c1c90b42526ac3e93041074b49a2cd0d6bb87d81a3e8640aad"
    }
  },
  {
    "ts": null,
    "headline": "Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring?",
    "summary": "The pharmaceutical company had a clinical setback earlier this year, but that's now in the rearview mirror.",
    "url": "https://finnhub.io/api/news?id=6c97149542ecd7f6824147befaaca282c3e6c0d52e78906a58b6a3d7cc8d7888",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759068900,
      "headline": "Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring?",
      "id": 136907468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharmaceutical company had a clinical setback earlier this year, but that's now in the rearview mirror.",
      "url": "https://finnhub.io/api/news?id=6c97149542ecd7f6824147befaaca282c3e6c0d52e78906a58b6a3d7cc8d7888"
    }
  },
  {
    "ts": null,
    "headline": "How Investors May Respond To Eli Lilly (LLY) FDA Approval of Inluriyo for Advanced Breast Cancer",
    "summary": "In the past week, Eli Lilly received U.S. FDA approval for Inluriyo, an oral estrogen receptor antagonist for estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following positive Phase 3 EMBER-3 results. This regulatory milestone expands Lilly's oncology portfolio by offering a new treatment option for patients with limited alternatives, underscoring Lilly's continued innovation in cancer care. We'll explore how this FDA approval could strengthen...",
    "url": "https://finnhub.io/api/news?id=1e5ac94dbe48b2f19c307d28350e0fc00d1fe3d0ba51f03b3ab54ef1d3be053c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759058015,
      "headline": "How Investors May Respond To Eli Lilly (LLY) FDA Approval of Inluriyo for Advanced Breast Cancer",
      "id": 136907469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the past week, Eli Lilly received U.S. FDA approval for Inluriyo, an oral estrogen receptor antagonist for estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following positive Phase 3 EMBER-3 results. This regulatory milestone expands Lilly's oncology portfolio by offering a new treatment option for patients with limited alternatives, underscoring Lilly's continued innovation in cancer care. We'll explore how this FDA approval could strengthen...",
      "url": "https://finnhub.io/api/news?id=1e5ac94dbe48b2f19c307d28350e0fc00d1fe3d0ba51f03b3ab54ef1d3be053c"
    }
  }
]